MCID: UTR024
MIFTS: 52

Uterine Carcinosarcoma

Categories: Rare diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Uterine Carcinosarcoma

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 50 56 52 14 69
Malignant Mixed Müllerian Tumor of the Corpus Uteri 50 56
Mixed Müllerian Cancer of Corpus Uteri 50 56
Carcinosarcoma of the Corpus Uteri 50 56
Malignant Mixed Müllerian Tumor of Corpus Uteri 50
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:6171
NCIt 47 C42700
SNOMED-CT 64 702369008
Orphanet 56 ORPHA213610
ICD10 via Orphanet 34 C54.9
UMLS 69 C0280630

Summaries for Uterine Carcinosarcoma

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

MalaCards based summary : Uterine Carcinosarcoma, also known as malignant mixed müllerian tumor of the corpus uteri, is related to adenosarcoma and colorectal cancer, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, liver and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Related Diseases for Uterine Carcinosarcoma

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 229)
id Related Disease Score Top Affiliating Genes
1 adenosarcoma 30.0 KIT PGR TP53
2 colorectal cancer 25.6 CTNNB1 EGFR ERBB2 ESR2 PIK3CA PTEN
3 gastritis 10.7 ERBB2 PGR
4 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
5 endocervicitis 10.7 ERBB2 TP53
6 glaucoma, hereditary 10.7 ERBB2 PGR
7 spinal cancer 10.7 ERBB2 PGR
8 animal phobia 10.7 ERBB2 TP53
9 blastema predominant kidney wilms' tumor 10.7 PGR TP53
10 fallopian tube squamous cell carcinoma 10.7 KIT TP53
11 central nervous system organ benign neoplasm 10.7 PGR TP53
12 lung adenoma 10.7 PGR TP53
13 mannose-binding lectin protein deficiency 10.6 KIT PGR
14 gastroesophageal junction adenocarcinoma 10.6 ERBB2 PGR
15 superficial basal cell carcinoma 10.6 KIT PGR
16 extracranial neuroblastoma 10.6 ERBB2 TP53
17 leiomyoma cutis 10.6 PGR TP53
18 intestinal perforation 10.6 PGR TP53
19 prostatic acinar adenocarcinoma 10.6 PGR TP53
20 intraductal breast myoepitheliosis 10.6 PGR TP53
21 pseudounicornuate uterus 10.6 KIT PGR
22 cystic kidney disease 10.6 ERBB2 TP53
23 ovarian mesodermal adenosarcoma 10.6 PGR TP53
24 desmoplastic small round cell tumor 10.6 CTNNB1 KIT
25 thyroid angiosarcoma 10.6 KIT PGR
26 infiltrating ureter transitional cell carcinoma 10.6 EGFR ERBB2
27 orbital lymphoma 10.6 ERBB2 TP53
28 breast pericanalicular fibroadenoma 10.6 PGR TP53
29 tendon sheath lipoma 10.5 PTGS2 TP53
30 liver angiosarcoma 10.5 KIT PGR
31 brain stem infarction 10.5 CTNNB1 KIT
32 retinal detachment 10.5 PGR TP53
33 pediatric infratentorial ependymoma 10.5 EGFR TP53
34 pancreatic agenesis 10.5 KIT TP53
35 central nervous system germ cell tumor 10.5 PGR TP53
36 sebaceous adenoma 10.5 KIT PGR
37 papilloma 10.5 CTNNB1 PGR
38 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.5 EGFR TP53
39 small intestinal vasoactive intestinal peptide producing tumor 10.4 KIT PTGS2
40 deafness, autosomal dominant 8/12 10.4 ESR2 PGR
41 childhood infratentorial neoplasm 10.4 EGFR TP53
42 rectal neoplasm 10.4 KIT PGR
43 otitis externa 10.4 ERBB2 PGR TP53
44 organ system benign neoplasm 10.4 ERBB2 PGR TP53
45 cartilage cancer 10.4 ERBB2 PGR TP53
46 immune system organ benign neoplasm 10.4 CTNNB1 TP53
47 benign breast phyllodes tumor 10.4 PGR PTEN
48 fallopian tube carcinosarcoma 10.4 ERBB2 PGR TP53
49 osteogenesis imperfecta 10.4 ESR2 PGR
50 sublingual gland adenoid cystic carcinoma 10.4 KIT PTEN

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma

Symptoms & Phenotypes for Uterine Carcinosarcoma

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.7 CTNNB1 ERBB2 KIT PGR PIK3CA PTEN
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.56 CTNNB1 EGFR ERBB2 PTEN
3 Increased cell death HMECs cells GR00103-A-0 9.43 PTEN TP53 CTNNB1 EGFR PGR PIK3CA
4 Increased cell viability after pRB stimulation GR00230-A-1 8.8 EGFR ERBB2 KIT

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

44 (show all 28)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
2 cellular MP:0005384 10.32 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
3 endocrine/exocrine gland MP:0005379 10.3 PTGS2 TP53 PIK3CA PTEN CTNNB1 EGFR
4 behavior/neurological MP:0005386 10.29 CTNNB1 ERBB2 ESR2 KIT PGR PIK3CA
5 homeostasis/metabolism MP:0005376 10.27 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
6 embryo MP:0005380 10.26 TP53 CTNNB1 EGFR ERBB2 KIT PGR
7 integument MP:0010771 10.25 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
8 growth/size/body region MP:0005378 10.24 CTNNB1 EGFR ERBB2 ESR2 KIT PIK3CA
9 digestive/alimentary MP:0005381 10.21 CTNNB1 EGFR ERBB2 ESR2 KIT PTEN
10 immune system MP:0005387 10.21 EGFR ESR2 KIT PGR PIK3CA PTEN
11 mortality/aging MP:0010768 10.21 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
12 muscle MP:0005369 10.19 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
13 hematopoietic system MP:0005397 10.18 CTNNB1 EGFR ESR2 KIT PGR PTEN
14 neoplasm MP:0002006 10.18 KIT PGR PIK3CA PTEN PTGS2 TP53
15 limbs/digits/tail MP:0005371 10.14 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
16 adipose tissue MP:0005375 10.11 EGFR ESR2 PIK3CA PTEN PTGS2 TP53
17 nervous system MP:0003631 10.11 CTNNB1 EGFR ERBB2 ESR2 KIT PIK3CA
18 liver/biliary system MP:0005370 10.07 TP53 CTNNB1 EGFR ESR2 KIT PTEN
19 normal MP:0002873 10.06 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
20 no phenotypic analysis MP:0003012 10.03 CTNNB1 EGFR ESR2 KIT PGR PIK3CA
21 craniofacial MP:0005382 10.02 CTNNB1 EGFR ERBB2 KIT TP53
22 hearing/vestibular/ear MP:0005377 9.98 CTNNB1 EGFR ESR2 KIT TP53
23 reproductive system MP:0005389 9.96 ERBB2 ESR2 KIT PGR PIK3CA PTEN
24 renal/urinary system MP:0005367 9.87 CTNNB1 EGFR ESR2 KIT PTEN PTGS2
25 pigmentation MP:0001186 9.77 CTNNB1 EGFR KIT PTEN TP53
26 respiratory system MP:0005388 9.76 KIT PTEN PTGS2 TP53 CTNNB1 EGFR
27 skeleton MP:0005390 9.65 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
28 vision/eye MP:0005391 9.17 PTGS2 TP53 CTNNB1 EGFR KIT PIK3CA

Drugs & Therapeutics for Uterine Carcinosarcoma

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Lenograstim Approved Phase 3 135968-09-1
5
Mechlorethamine Approved Phase 3 51-75-2 4033
6
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
7
Mesna Approved Phase 3 3375-50-6 598
8
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
11
Doxil Approved June 1999 Phase 3,Phase 2 31703
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
13 Alkylating Agents Phase 3,Phase 2
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Isophosphamide mustard Phase 3
17 Anti-Bacterial Agents Phase 3,Phase 2
18 Antibiotics, Antitubercular Phase 3,Phase 2
19 Topoisomerase Inhibitors Phase 3,Phase 2
20 Anti-Allergic Agents Phase 3
21 Antipruritics Phase 3
22 Dermatologic Agents Phase 3
23 Gastrointestinal Agents Phase 3
24 Histamine Antagonists Phase 3
25 Histamine H1 Antagonists Phase 3
26
Histamine Phosphate Phase 3 51-74-1 65513
27 Neurotransmitter Agents Phase 3
28
Serotonin Phase 3 50-67-9 5202
29 Serotonin Agents Phase 3
30 Serotonin Antagonists Phase 3
31
Gemcitabine Approved Phase 2 95058-81-4 60750
32
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
35
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
36
Everolimus Approved Phase 2 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
39
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
40
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
41
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
42
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
43
Metformin Approved Phase 2 657-24-9 14219 4091
44
nivolumab Approved Phase 2 946414-94-4
45
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
48
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
49
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
50
Saracatinib Investigational Phase 2 379231-04-6

Interventional clinical trials:

(show all 42)

id Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
4 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
8 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
9 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
10 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
11 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
12 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
13 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
14 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
15 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
16 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
17 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
18 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
19 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
20 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
23 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
24 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
25 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
26 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
27 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
28 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
29 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
30 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
31 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
32 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Active, not recruiting NCT01168232 Phase 2 ixabepilone
33 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
34 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
35 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
36 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
37 Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003156 Phase 2 topotecan hydrochloride
38 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
39 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Recruiting NCT01991808 Phase 1
40 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
41 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 paclitaxel;carboplatin
42 Lymph Node Counts in Endometrial Cancer Staging Completed NCT02335775

Search NIH Clinical Center for Uterine Carcinosarcoma

Genetic Tests for Uterine Carcinosarcoma

Anatomical Context for Uterine Carcinosarcoma

MalaCards organs/tissues related to Uterine Carcinosarcoma:

39
Uterus, Liver, Lymph Node, Endothelial, Ovary, Lung

Publications for Uterine Carcinosarcoma

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 176)
id Title Authors Year
1
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. ( 28930812 )
2017
2
Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. ( 27931750 )
2017
3
Identification of distinct molecular subtypes of uterine carcinosarcoma. ( 28178664 )
2017
4
Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma. ( 28836024 )
2017
5
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. ( 28121642 )
2017
6
Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports. ( 28761924 )
2017
7
Prognostic value of metabolic parameters determined by preoperative A^a8,F-FDG PET/CT in patients with uterine carcinosarcoma. ( 28541634 )
2017
8
Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. ( 28215838 )
2017
9
Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. ( 28657223 )
2017
10
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report. ( 28424084 )
2017
11
Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis. ( 28574930 )
2017
12
A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. ( 28584958 )
2017
13
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. ( 28193280 )
2017
14
Integrated Molecular Characterization of Uterine Carcinosarcoma. ( 28292439 )
2017
15
Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. ( 28088687 )
2017
16
Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. ( 28704324 )
2017
17
Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. ( 28654573 )
2017
18
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28317560 )
2017
19
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28318642 )
2017
20
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. ( 26896827 )
2016
21
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( 27172745 )
2016
22
Prognostic impact of primary tumor SUVmax on preoperative (18)F-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography in endometrial cancer and uterine carcinosarcoma. ( 27703679 )
2016
23
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. ( 27441069 )
2016
24
Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). ( 27550404 )
2016
25
Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma. ( 27779297 )
2016
26
Prognostic value of total lesion glycolysis on preoperative (18)F-FDG PET/CT in patients with uterine carcinosarcoma. ( 26883331 )
2016
27
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. ( 27072806 )
2016
28
Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. ( 26941453 )
2016
29
Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. ( 27009459 )
2016
30
Uterine carcinosarcoma including angiosarcoma: A short case report. ( 27592347 )
2016
31
Utility of histogram analysis of apparent diffusion coefficient maps obtained using 3.0T MRI for distinguishing uterine carcinosarcoma from endometrial carcinoma. ( 26605502 )
2016
32
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. ( 27889902 )
2016
33
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. ( 27052653 )
2016
34
Comparison of MRI and (18)F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. ( 26777990 )
2016
35
RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma. ( 27121792 )
2016
36
Unusual Cutaneous Metastasis of Uterine Carcinosarcoma: A Case Report and Review of the Literature. ( 26675357 )
2016
37
Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic Platform. ( 27794476 )
2016
38
Clinical outcomes of uterine carcinosarcoma: results of 94 patients. ( 25611900 )
2015
39
The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. ( 26509850 )
2015
40
Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: A retrospective cohort study. ( 26476418 )
2015
41
Review of Recommended Treatment of Uterine Carcinosarcoma. ( 26374341 )
2015
42
Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. ( 25633654 )
2015
43
Uterine carcinosarcoma/malignant mixed MA1llerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy. ( 26404129 )
2015
44
Clinically aggressive "low-grade" uterine carcinosarcoma: A case report. ( 26793763 )
2015
45
Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis. ( 26307402 )
2015
46
Role of TGF-I^ signaling in uterine carcinosarcoma. ( 25918253 )
2015
47
URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis. ( 26328264 )
2015
48
The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival: A Reassessment Based on Mature Data. ( 26222488 )
2015
49
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. ( 26348313 )
2015
50
Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer (G3EC) patients: a comparative study. ( 26463439 )
2015

Variations for Uterine Carcinosarcoma

ClinVar genetic disease variations for Uterine Carcinosarcoma:

6 (show all 44)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
12 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
13 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
23 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
24 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
25 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
26 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
27 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
28 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
29 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
30 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
31 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
32 PPP2R1A NM_014225.5(PPP2R1A): c.536C> T (p.Pro179Leu) single nucleotide variant Pathogenic/Likely pathogenic rs786205228 GRCh38 Chromosome 19, 52212718: 52212718
33 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
34 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
35 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
37 PIK3CA NM_006218.3(PIK3CA): c.1637A> C (p.Gln546Pro) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
38 PIK3CA NM_006218.3(PIK3CA): c.1637A> T (p.Gln546Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
39 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
40 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
41 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
42 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
43 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic/Likely pathogenic rs1057519981 GRCh37 Chromosome 17, 7577569: 7577569
44 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Expression for Uterine Carcinosarcoma

Search GEO for disease gene expression data for Uterine Carcinosarcoma.

Pathways for Uterine Carcinosarcoma

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CTNNB1 EGFR ERBB2 KIT PIK3CA PTEN
2
Show member pathways
13.72 CTNNB1 EGFR ERBB2 ESR2 KIT PTEN
3
Show member pathways
13.69 EGFR ERBB2 ESR2 KIT PGR PTEN
4
Show member pathways
13.34 EGFR ERBB2 KIT PIK3CA PTEN TP53
5
Show member pathways
13.26 EGFR ERBB2 KIT PIK3CA PTGS2 TP53
6
Show member pathways
13.19 CTNNB1 EGFR ERBB2 KIT PTEN
7
Show member pathways
13.17 CTNNB1 EGFR ERBB2 ESR2 KIT
8
Show member pathways
12.79 CTNNB1 EGFR ERBB2 PIK3CA PTEN PTGS2
9
Show member pathways
12.77 EGFR ERBB2 PIK3CA PTEN
10
Show member pathways
12.68 CTNNB1 EGFR PIK3CA PTEN
11
Show member pathways
12.68 CTNNB1 ERBB2 PIK3CA PTEN PTGS2 TP53
12
Show member pathways
12.65 CTNNB1 EGFR KIT PIK3CA
13
Show member pathways
12.55 EGFR ERBB2 KIT PIK3CA PTEN TP53
14
Show member pathways
12.53 CTNNB1 EGFR ERBB2 PIK3CA TP53
15 12.45 CTNNB1 EGFR KIT PIK3CA PTEN PTGS2
16
Show member pathways
12.43 EGFR ERBB2 PIK3CA PTEN TP53
17
Show member pathways
12.42 ERBB2 ESR2 PIK3CA PTEN
18
Show member pathways
12.42 CTNNB1 EGFR ERBB2 PIK3CA TP53
19
Show member pathways
12.36 CTNNB1 EGFR ERBB2 PIK3CA TP53
20 12.27 EGFR ERBB2 PIK3CA PTEN PTGS2 TP53
21
Show member pathways
12.26 EGFR ERBB2 PIK3CA TP53
22
Show member pathways
12.22 EGFR ERBB2 ESR2 PIK3CA PTGS2
23
Show member pathways
12.19 EGFR ERBB2 PIK3CA PTEN TP53
24 12.16 CTNNB1 EGFR PTGS2 TP53
25 12.16 CTNNB1 EGFR ERBB2 PIK3CA TP53
26
Show member pathways
12.16 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
27 12.15 CTNNB1 EGFR ERBB2 KIT PIK3CA PTEN
28 12.12 CTNNB1 EGFR PTEN TP53
29 12.11 EGFR ERBB2 PTEN
30
Show member pathways
12.11 EGFR ERBB2 PIK3CA PTEN
31
Show member pathways
12.1 KIT PIK3CA PTEN
32 12.04 EGFR ERBB2 KIT
33 12.03 CTNNB1 PIK3CA TP53
34
Show member pathways
12.03 EGFR PIK3CA PTEN
35 12 EGFR PTEN TP53
36
Show member pathways
12 EGFR ERBB2 PIK3CA TP53
37 11.99 EGFR PIK3CA TP53
38
Show member pathways
11.97 CTNNB1 EGFR ERBB2 PIK3CA PTEN
39 11.95 EGFR PTGS2 TP53
40 11.94 PIK3CA PTEN TP53
41 11.94 CTNNB1 EGFR PTEN TP53
42 11.93 CTNNB1 PIK3CA TP53
43
Show member pathways
11.92 EGFR ERBB2 PGR PIK3CA
44 11.85 EGFR ERBB2 PIK3CA
45
Show member pathways
11.82 EGFR ERBB2 KIT
46 11.81 CTNNB1 EGFR PTEN
47 11.78 PIK3CA PTEN PTGS2 TP53
48 11.72 CTNNB1 ERBB2 PIK3CA PTEN TP53
49 11.71 EGFR ERBB2 TP53
50 11.7 ERBB2 PIK3CA TP53

GO Terms for Uterine Carcinosarcoma

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.23 CTNNB1 EGFR ERBB2 KIT PGR PTEN
2 basolateral plasma membrane GO:0016323 9.13 CTNNB1 EGFR ERBB2

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 regulation of transcription from RNA polymerase II promoter GO:0006357 9.93 CTNNB1 EGFR ERBB2 KIT
2 negative regulation of cell proliferation GO:0008285 9.9 CTNNB1 PTEN PTGS2 TP53
3 positive regulation of apoptotic process GO:0043065 9.85 CTNNB1 PTEN PTGS2 TP53
4 positive regulation of cell proliferation GO:0008284 9.85 CTNNB1 EGFR KIT PTEN PTGS2
5 regulation of cell proliferation GO:0042127 9.81 CTNNB1 EGFR KIT PTGS2
6 protein autophosphorylation GO:0046777 9.8 EGFR ERBB2 KIT
7 cell proliferation GO:0008283 9.8 CTNNB1 EGFR ERBB2 PTEN TP53
8 negative regulation of apoptotic process GO:0043066 9.79 EGFR PTEN TP53
9 peptidyl-tyrosine phosphorylation GO:0018108 9.79 EGFR ERBB2 KIT
10 response to organic cyclic compound GO:0014070 9.77 EGFR PTEN PTGS2
11 positive regulation of gene expression GO:0010628 9.77 CTNNB1 ERBB2 KIT PTEN TP53
12 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.75 EGFR ERBB2 KIT
13 cellular response to hypoxia GO:0071456 9.73 PTEN PTGS2 TP53
14 positive regulation of MAP kinase activity GO:0043406 9.7 EGFR ERBB2 KIT
15 cellular response to growth factor stimulus GO:0071363 9.67 CTNNB1 EGFR ERBB2
16 regulation of ERK1 and ERK2 cascade GO:0070372 9.64 EGFR ERBB2
17 vasculature development GO:0001944 9.63 CTNNB1 PIK3CA
18 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.62 CTNNB1 ESR2 KIT PTEN
19 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.61 EGFR PTGS2
20 ERBB2 signaling pathway GO:0038128 9.61 EGFR ERBB2 PIK3CA
21 negative regulation of ERBB signaling pathway GO:1901185 9.58 EGFR ERBB2
22 phosphatidylinositol phosphorylation GO:0046854 9.56 EGFR ERBB2 KIT PIK3CA
23 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.54 PIK3CA PTGS2
24 signal transduction by protein phosphorylation GO:0023014 9.48 ERBB2 KIT
25 response to estradiol GO:0032355 9.46 CTNNB1 EGFR PTEN PTGS2
26 tongue development GO:0043586 9.27 EGFR
27 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.26 EGFR ERBB2 KIT PIK3CA
28 phosphatidylinositol-mediated signaling GO:0048015 9.1 EGFR ERBB2 KIT PIK3CA PTEN TP53
29 signal transduction GO:0007165 10.12 CTNNB1 EGFR ERBB2 ESR2 KIT PGR

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.78 CTNNB1 EGFR ERBB2 TP53
2 protein kinase binding GO:0019901 9.73 CTNNB1 EGFR PTEN TP53
3 lipid binding GO:0008289 9.67 ESR2 PGR PTEN PTGS2
4 protein tyrosine kinase activity GO:0004713 9.63 EGFR ERBB2 KIT
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 EGFR ERBB2 KIT
6 protein phosphatase binding GO:0019903 9.56 CTNNB1 EGFR ERBB2 TP53
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 EGFR ERBB2 KIT
8 steroid binding GO:0005496 9.49 ESR2 PGR
9 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 EGFR ERBB2 KIT PIK3CA
10 enzyme binding GO:0019899 9.17 CTNNB1 EGFR ESR2 PGR PTEN PTGS2
11 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.13 EGFR ERBB2 KIT

Sources for Uterine Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....